著者

Yusuke Ainoda Nozomi Takeshita Ryota Hase Takahiro Mikawa Naoto Hosokawa Ichiro Kawamura Hanako Kurai Masahiro Abe Muneyoshi Kimura Hideki Araoka Takahiro Fujita Kyoichi Totsuka Kazuhisa Mezaki Noritaka Sekiya Norio Ohmagari

出版者

国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会

雑誌

Japanese Journal of Infectious Diseases (ISSN:13446304)

巻号頁・発行日

pp.JJID.2016.130, (Released:2016-12-22)

参考文献数

17

被引用文献数

7

---

Staphylococcus lugdunensis (SL) is a highly pathogenic bacterium compared to other coagulase-negative Staphylococcus spp. (CoNS). However, in Japan, data for this pathogen are sparse, and the current prevalence of SL bacteremia is unknown.A prospective multicenter study across five facilities was performed to investigate the prevalence of SL in blood culture specimens. There were 3,284 patients with positive blood cultures, and 2,478 patients had bacteremia. Among patients with bacteremia, 7 patients (0.28%) had SL bacteremia. A total of 281 patients had CoNS bacteremia, and SL accounted for 2.49% of these cases. Of the 7 patients with SL bacteremia, 1 patient (14.3%) had infective endocarditis, and 1 patient (14.3%) died within 30 days. In this study, SL resulted in the development of bacteremia in select patients. Clinicians in Japan should be aware of the prevalence of SL and the complications of SL bacteremia.

著者

Naoto Okada Shuji Fushitani Momoyo Azuma Shingen Nakamura Toshimi Nakamura Kazuhiko Teraoka Hiroyoshi Watanabe Masahiro Abe Kazuyoshi Kawazoe Keisuke Ishizawa

出版者

公益社団法人日本薬学会

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.39, no.2, pp.295-300, 2016-02-01 (Released:2016-02-01)

参考文献数

16

被引用文献数

21

---

The therapeutic effects of anti-methicillin-resistant Staphylococcus aureus (MRSA) agents, vancomycin (VCM), teicoplanin (TEIC), and arbekacin (ABK), depend on their concentrations in blood. Therefore, therapeutic drug monitoring (TDM) is important when these antibiotics are used. In the hematological ward at Tokushima University Hospital, pharmacists have ordered the measurement of blood VCM, TEIC, and ABK concentrations to promote the use of TDM in accordance with an agreed protocol since 2013. Moreover, the infection control team includes several medical disciplines and has advised on the optimal treatment using VCM, TEIC, and ABK since 2013. This study aimed to investigate the clinical effectiveness of these pharmacist interventions. We retrospectively studied 145 cases in which patients were treated with VCM, TEIC, or ABK between January 2012 and December 2013 in the hematological ward at Tokushima University Hospital. The patients were divided into a control group (71 cases) and an intervention group (74 cases), and their clinical outcomes were compared. The rate of achievement of effective drug concentrations significantly increased in the intervention group (74%), compared to the rate in the control group (55%). Moreover, univariate and multivariate Cox proportional hazard regression revealed that pharmacist intervention and appropriate concentrations of anti-MRSA agents were independent factors associated with reduced hospitalization periods in patients with lymphoma. Our study revealed that proactive pharmacist intervention may improve the therapeutic effect of anti-MRSA agents in hematology ward patients.

著者

Yusuke Ainoda Nozomi Takeshita Ryota Hase Takahiro Mikawa Naoto Hosokawa Ichiro Kawamura Hanako Kurai Masahiro Abe Muneyoshi Kimura Hideki Araoka Takahiro Fujita Kyoichi Totsuka Kazuhisa Mezaki Noritaka Sekiya Norio Ohmagari

出版者

National Institute of Infectious Diseases

雑誌

Japanese Journal of Infectious Diseases (ISSN:13446304)

巻号頁・発行日

vol.70, no.4, pp.405-407, 2017 (Released:2017-07-24)

参考文献数

17

被引用文献数

7 7

---

Staphylococcus lugdunensis (SL) is a bacterium with a highly pathogenicity than most other coagulase-negative Staphylococcus spp. (CoNS). In Japan, data on this pathogen are sparse, and the current prevalence of SL bacteremia is unknown. Therefore, we investigated the prevalence of SL in blood culture specimens in a prospective multicenter study across 5 facilities. A total of 3,284 patients had positive blood cultures, and 2,478 patients had bacteremia. Among the patients with bacteremia, 7 patients (0.28%) had SL bacteremia. A total of 281 patients had CoNS bacteremia, with SL accounting for 2.49% of these cases. Of the 7 patients with SL bacteremia, 1 patient (14.3%) had infective endocarditis, and 1 patient (14.3%) died within 30 days. In this study, SL resulted in the development of bacteremia in select patients. Clinicians in Japan should be aware of the prevalence of SL and the complications of SL bacteremia.

著者

Masahiro Kitada Yoshinobu Ohsaki Shunsuke Yasuda Masahiro Abe Nana Yoshida Satoshi Okazaki Kei Ishibashi

出版者

The Editorial Committee of Annals of Thoracic and Cardiovascular Surgery

雑誌

Annals of Thoracic and Cardiovascular Surgery (ISSN:13411098)

巻号頁・発行日

pp.oa.20-00014, (Released:2020-06-10)

参考文献数

18

著者

Hozumi Tashima Yuka Endo Naoto Okada Shingen Nakamura Kumiko Kagawa Shiro Fujii Hirokazu Miki Keisuke Ishizawa Masahiro Abe Youichi Sato

出版者

International Society of Personalized Medicne

雑誌

Personalized Medicine Universe (ISSN:21864969)

巻号頁・発行日

vol.10, pp.1-6, 2021-12-01 (Released:2022-01-07)

参考文献数

9

---

Purpose: Cytarabine arabinoside (Ara-C) is an anti-metabolite that is commonly used as a therapeutic agent for acute leukemia; however, it can cause adverse drug reactions, such as digestive disorders, rashes, and fever. Therefore, identification of gene markers that can accurately predict the development of adverse drug reactions is useful for selecting effective drugs for therapy. After entering the cells, Ara-C is metabolized to Ara-C triphosphate, which inhibits DNA synthesis and exhibits antitumor activity. Therefore, we conducted an association study between the adverse reactions to cytarabine therapy and single nucleotide polymorphisms (SNPs) in cytarabine metabolic genes.Methods: Among the patients treated with cytarabine at the Department of Hematology at Tokushima University Hospital, 46 patients provided informed consent and were included in this study. We selected 14 tag SNPs located in nine genes that are involved in the cytarabine metabolic pathway; these SNPs were genotyped using the polymerase chain reaction (PCR) restriction fragment length polymorphism (RFLP) technique. Association analyses between adverse reactions to Ara-C therapy and SNPs were performed using logistic regression analysis.Results: The rs9394992 polymorphism in the SLC29A1 gene and rs3886768 polymorphism in the DCTD gene were associated with the development of rash after Ara-C therapy. The rs7277 polymorphism in the DCTD gene was associated with fever, and the rs16945930 polymorphism in the ABCC11 gene was associated with sore throat.Conclusions: Our findings suggest that SNPs in the Ara-C metabolic genes influence the development of adverse reactions to Ara-C, and the results suggest that these genes can be predictive of adverse reactions to Ara-C therapy.

著者

Naoto Okada Kazuyoshi Kawazoe Kazuhiko Teraoka Toshihide Kujime Masahiro Abe Yasuo Shinohara Kazuo Minakuchi

出版者

The Pharmaceutical Society of Japan

雑誌

Biological and Pharmaceutical Bulletin (ISSN:09186158)

巻号頁・発行日

vol.36, no.10, pp.1622-1626, 2013-10-01 (Released:2013-10-01)

参考文献数

21

被引用文献数

27 42

---

Denosumab, a fully human monoclonal antibody that inhibits the receptor activator of nuclear factor-κB ligand, inhibits the activation of osteoclasts. Some clinical trials have shown that denosumab suppresses bone resorption in patients with advanced cancer, but hypocalcemia has been reported as a serious adverse effect after the administration of denosumab. It is difficult to predict hypocalcemia in such cases because the risk factors for denosumab-induced hypocalcemia have not been reported. Accordingly, the aim of the present study was to identify the risk factors for hypocalcemia induced by denosumab. We retrospectively reviewed the records of patients who had received denosumab at Tokushima University Hospital between April 2012 and May 2013. Fifty-three patients were analyzed and eleven patients had hypocalcemia after administration of denosumab. Univariate logistic regression analysis revealed that the patients who had not been administered zoledronic acid before receiving denosumab or had lower creatinine clearance (CCr) appeared to have a higher risk of hypocalcemia (p<0.05). The cut off value of CCr was 50.4 mL/min calculated by receiver-operator characteristics curves. Moreover, multivariate logistic regression analysis revealed that non-administration of zoledronic acid (odds ratio 10.43, p<0.05) and CCr less than 50.0 mL/min (odds ratio 5.90, p<0.05) were independent risk factors for denosumab-induced hypocalcemia. These findings provide useful information regarding the monitoring of hypocalcemia in patients receiving denosumab.